制药公司对CMS提出挑战, Pharma company challenges CMS over hemp cannabinoid reimbursement for seniors.

一家制药公司正在挑战CMS对其计划向老年人退还大麻衍生类大麻素产品的要求, 认为该政策绕过了必要的FDA安全标准并造成不公平竞争. A pharmaceutical company is challenging CMS over its plan to reimburse hemp-derived cannabinoid products for seniors, arguing the policy bypasses necessary FDA safety standards and creates unfair competition. 案件突出了联邦医疗保健计划是否应该在获得完全临床验证之前扩大治疗机会的争议. The case highlights a dispute over whether federal healthcare programs should expand access to therapies before they have full clinical validation.